Powered by

-Cesca Therapeutics Receives 510(k) Clearance to Market Its AXP II AutoXpress Platform for Clinical Cord Blood Banking

Nov 20, 2018 - ENP Newswire

RANCHO CORDOVA - Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its device subsidiary, ThermoGenesis Corp., has received 510(k) clearance from the U.S. Food Drug Administration (FDA) for its proprietary AXP II AutoXpress Platform (AXP II) for clinical blood banking.

The AXP II, in combination with the Company's companion, single-use, cell separation set provides automated, rapid ...